Plain-English translation of NCT06363994 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Mantle Cell Lymphoma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a medication called , when added to two standard lymphoma drugs (bendamustine and ), works better than the standard drugs alone. About 476 people with a type of blood cancer called mantle cell lymphoma will be randomly assigned to receive either the new combination or the standard treatment. The researchers want to see if this medication improves how well the treatment works and whether it's safe to use.
Mantle cell lymphoma is a serious cancer that can be hard to treat, and doctors are looking for ways to improve outcomes for patients who are newly diagnosed. This trial exists to find out whether this medication can help make existing treatments more effective for people who may not be candidates for more intensive therapies.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups: one group receives the new medication plus the two standard drugs, and the other group receives the two standard drugs alone. Neither you nor your doctors will know which group you're in (this is called a double-blind study). You will have regular visits to receive your treatment, have blood tests, and have scans to see how well the treatment is working. The trial involves doctors and hospitals in multiple countries working together to gather information about whether this combination approach is safer and more effective.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China